Molecure (MOC) Q2 2026 earnings summary

Executive summary

• Focus on R&D of small-molecule drugs for high unmet clinical needs, especially oncology and respiratory diseases.

• Financial statements cover the six months ended June 30, 2026, with comparative data for 2025.

• Company remains in the R&D phase, incurring significant development costs before commercialization.

• Cash and equivalents at June 30, 2026, totaled PLN 24.9 million.

• Additional financing will be required in Q1 2027 to maintain planned R&D activities.

Financial highlights

• Operating revenue for H1 2026: PLN 1.86 million, down from PLN 3.52 million in H1 2025.

• Operating loss: PLN -6.34 million (H1 2026) vs. PLN -9.13 million (H1 2025).

• Net loss: PLN -6.31 million (H1 2026) vs. PLN -8.52 million (H1 2025).

• Net cash from operating activities: PLN -1.39 million (H1 2026) vs. PLN -10.64 million (H1 2025).

• Net cash from financing activities: PLN 20.6 million (H1 2026), mainly from share issuance.

• Total assets at June 30, 2026: PLN 112.6 million; equity: PLN 101.3 million.

• Basic and diluted loss per share: PLN -0.29 (H1 2026) vs. PLN -0.41 (H1 2025).

Outlook and guidance

• Management expects the need for additional funding in Q1 2027 to continue R&D programs.

• Ongoing efforts to secure capital through equity or partnering transactions.

• Flexibility to adjust R&D timelines and expenditures if needed.